CD274 and neoplasm: Immunotherapy reduced the risk of disease relapse by 34% (HR = 0.66, 95% CI: 0.50–0.88) in stage II-IIIA NSCLC patients with expression of PD-L1 on ≥1% of tumor cells compared with BSC.